Aethlon Medical, Inc (NASDAQ: AEMD) Reports Revenues Of $659,000 In 2021 From Government Contracts

Aethlon Medical, Inc (NASDAQ: AEMD) posted revenues of $659,000 (up 1.38% YoY) in 2021 from government contracts.

Its loss increased to $7.9 million in 2021 compared to $6.4 million in 2020.

The company’s operational spending increased to $8.6 million (up 30.3% YoY) in 2021. It is on the backdrop of an increase in G&A and payroll and payroll-related expenses.

Glycosolated SARS-COV-2 belongs to the coronavirus family of SARS-CoV, the original SARS virus, and the MERS virus. The Aethlon Hemopurifier showed its capability to bind and eliminate glycosolated viruses such as SARS-CoV-2 from the blood.

FDA approves evaluation of Hemopurifier in humans

On June 17, 2020, the US FDA allowed Aethlon to test its hemopurifier in humans infected with SARS-CoV-2. In the new feasibility trial, the company would enroll 40 subjects infected with confirmed COVID-19 across 20 centers in the US.

It will select the COVID-19 infected patients and admitted to the ICU and suffering from acute lung injury or life-threatening disease.

The primary endpoint of this feasibility study is a significant drop in the circulating virus besides assessing the safety aspects. In addition, Aethlon will also assess the clinical outcome of its hemopurifier in patients with COVID-19.

The company will conduct the preliminary clinical trials at Loma Linda Hospital in Loma Linda, California; Hoag Hospital – Irvine in Irvine, California; and Hoag Memorial Hospital Presbyterian in Newport Beach, California.

The company also signed agreements for clinical trials at these hospitals. It also received IRB from Hoag hospitals. Aethlon plans to commence patient recruitment for the clinical study.

Publishes a manuscript

Aethlon cured two patients with SARS-COV-2 using its Hemopurifier. In addition, the company recently released a manuscript detailing the treatments under the title – Removal of Exosomes, Whole Virus, COVID-19 Spike Protein, Exosomal microRNAs using its Hemopurifier Lectin-Affinity Cartridge.

The company used Hemopurifier in nine sessions in patients who are critically ill with coronavirus. As a result, they have entirely recovered from the COVID-19.

In the first case study involving a patient with SARS-COV-2 positive at an entry to the hospital, the company removed exosomes using its Hemopurifier on day 22. Then, it discharged the patient after administering eight Hemopurifier treatments. The patient did not show any complications during the treatment.

The second covid-19 infected patient also showed SARS-CoV-2 virus in vivo removal after administering a six-hour Hemopurifier treatment.